AMPH · CIK 0001297184
What Amphastar Pharmaceuticals, Inc. told the SEC could break it.
Amphastar's register is dominated by concentration on both sides of its business. Its sales funnel through a few US wholesalers and group purchasing organizations — three customers were about 65% of net revenues in 2025 — and ongoing consolidation gives them more pricing leverage. Its supply chain is just as narrow, depending on multiple single-source suppliers, a third party to manufacture BAQSIMI, and a single facility in Éragny-sur-Epte, France, for its porcine insulin and RHI active ingredients. Layered on top, US tariffs — Section 301, fentanyl-related duties of 10-35% on Chinese, Mexican and Canadian imports, and reciprocal tariffs — could raise the cost of imported materials for its US, France and China manufacturing, despite some pharmaceutical exemptions.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- Three wholesaler/GPO customers = ~65% of net revenueshigh
A significant proportion of sales go to relatively few U.S. wholesalers and group purchasing organizations; three customers accounted for approximately 65% of total net revenues in 2025 (64% in 2024, 60% in 2023), and ongoing consolidation increases their purchasing leverage and pricing pressure.
“Sales to three of these customers for the years ended December 31, 2025, 2024, and 2023, respectively, accounted for approximately 65%, 64%, and 60% of our total 41 Table of Contents net revenues, respectively.”
SEC filing →As of 2026
Sole-source dependency
- Multiple single-source suppliers; third-party BAQSIMI manufacture; single France API sitehigh
Amphastar's supply chain depends on multiple single-source suppliers and on a third party for the manufacture of BAQSIMI, and its porcine insulin and RHI APIs are made at a single facility in Éragny-sur-Epte, France — disruptions to any of which could materially affect the business.
“our success depends on the integrity of our supply chain, including multiple single source suppliers, and reliance on a third party for the manufacture of BAQSIMI ® the disruption of which could negatively impact our business”
SEC filing →As of 2026
Regulatory & policy
- U.S. tariffs on imported pharma inputs (China/Mexico/Canada)medium
U.S. tariffs — Section 301 on China/Brazil, fentanyl-related 10–35% tariffs on Chinese/Mexican/Canadian-origin items, and Section 232 commodity tariffs — could raise the cost of imported materials for Amphastar's US/France/China manufacturing, despite exemptions for certain pharmaceutical products.
“between February 4, 2025 and February 23, 2026, the U.S. government imposed “fentanyl-related” tariffs of 10% to 35% on the import of almost all Chinese-, Mexican-, and Canadian-origin items with an exception for items qualifying for duty-free treatment under the U.S.-Mexico-Canada Agreement, as well as additional “reciprocal” tariffs of 10% to 125% on certain products of most other U.S. trading partners, including China, after April 2025, with exemptions for certain pharmaceutical products, semiconductors, and consumer electronics.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“We currently own and operate facilities that manufacture raw materials and APIs for our products and product candidates and those of our customers and partners, including insulin API for MannKind.”
Cited →“Currently, the only source of insulin that we have qualified for Afrezza is manufactured by Amphastar.”
Cited →
Its suppliers
“we continued to assume distribution responsibilities for BAQSIMI ® from Lilly to our customers in the United States and certain other countries throughout 2024.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch